Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Finished Goods (2023 - 2025)

China SXT Pharmaceuticals (SXTC) has 3 years of Finished Goods data on record, last reported at $448668.0 in Q1 2025.

  • For Q1 2025, Finished Goods fell 18.97% year-over-year to $448668.0; the TTM value through Mar 2025 reached $448668.0, down 18.97%, while the annual FY2025 figure was $448668.0, 18.97% down from the prior year.
  • Finished Goods reached $448668.0 in Q1 2025 per SXTC's latest filing, down from $553682.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $553682.0 in Q1 2024 and bottomed at $446866.0 in Q1 2023.
  • Average Finished Goods over 3 years is $483072.0, with a median of $448668.0 recorded in 2025.
  • Peak YoY movement for Finished Goods: grew 23.9% in 2024, then decreased 18.97% in 2025.
  • A 3-year view of Finished Goods shows it stood at $446866.0 in 2023, then increased by 23.9% to $553682.0 in 2024, then fell by 18.97% to $448668.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $448668.0 in Q1 2025, $553682.0 in Q1 2024, and $446866.0 in Q1 2023.